Browse by author
Lookup NU author(s): Dr Joyce Nutt, Kieran O'Toole, Dr Fiona Black, Amy Quinn, Professor Alan Calvert, Professor Ruth Plummer, Professor John LunecORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
BACKGROUND: The standard treatment of choice for malignant pleural mesothelioma is chemotherapy with pemetrexed and platinum, but the clinical outcome is poor. This study investigates the response to pemetrexed in a panel of eight mesothelioma cell lines and the clinical outcome for patients treated with pemetrexed in relation to folate receptor alpha (FR alpha). METHODS: Cell lines were treated with pemetrexed to determine the concentration that reduced growth to 50% (GI(50)). FR alpha expression was determined by western blotting and that of FR alpha, reduced folate carrier (RFC) and proton-coupled folate transporter (PCFT) by real-time quantitative RT-PCR. Immunohistochemistry for FR alpha was carried out on 62 paraffin-embedded samples of mesothelioma from patients who were subsequently treated with pemetrexed. RESULTS: A wide range of GI(50) values was obtained for the cell lines, H2452 cells being the most sensitive (GI(50) 22 nM) and RS5 cells having a GI(50) value greater than 10 mu M. No FR alpha protein was detected in any cell line, and there was no relationship between sensitivity and expression of folate transporters. FR alpha was detected in 39% of tumour samples, generally in a small percentage of cells. There was no correlation between the presence of FR alpha and the outcome of pemetrexed treatment, and no significant difference between histological subtypes. CONCLUSION: Response to treatment with pemetrexed does not depend on the presence of FR alpha. British Journal of Cancer (2010) 102, 553-560. doi:10.1038/sj.bjc.6605501 www.bjcancer.com Published online 5 January 2010 (C) 2010 Cancer Research UK
Author(s): Nutt JE, Razak ARA, O'Toole K, Black F, Quinn AE, Calvert AH, Plummer ER, Lunec J
Publication type: Article
Publication status: Published
Journal: British Journal of Cancer
Year: 2010
Volume: 102
Issue: 3
Pages: 553-560
Print publication date: 05/01/2010
ISSN (print): 0007-0920
ISSN (electronic): 1532-1827
Publisher: Nature Publishing Group
URL: http://dx.doi.org/10.1038/sj.bjc.6605501
DOI: 10.1038/sj.bjc.6605501
Altmetrics provided by Altmetric